FDA Approves Expanded MRI Compatibility for Emerging Spinal Cord Stimulation Modality
Expanded MRI labeling for Abbott’s Proclaim™ XR Spinal Cord Stimulation System may facilitate increased efficiency and quality of MRI scans.
The Food and Drug Administration (FDA) has reportedly approved new labeling that removes limits on lead tip allocation and the amount of radiofrequency power employed with MRI scans in conjunction with the Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode™ leads.
The expanded MRI labeling enables clinicians to place the Octrode lead tips anywhere along the spine without hampering the use of MRI scans for approved conditions, according to Abbott, the manufacturer of the Proclaim XR SCS System. The company said the new labeling also removes restrictions on the use of radiofrequency energy for patients with the Proclaim XR SCS System if the MRI device is in normal operating mode.
There may be increased efficiency and safety as well. While the FDA usually requires radiologists to pause MRIs for 30 to 60 minutes between scan cycles due to potential concerns about radiofrequency energy heating up an implant and damaging surrounding tissue, Abbott noted the expanded MRI labeling allows radiologists to wait only 30 minutes between scan cycles of 30 minutes when assessing patients who have an implanted Proclaim XR SCS System.
“The expanded labeling and reduced scan time address two major issues we face with these implantable devices. By improving the quality of imaging, as well as the experience for both the patient and the radiologist, I can now enable more of my existing and new patients to benefit from MRI scans improving their care,” explained Steven Falowski, M.D., a neurosurgeon who is affiliated with Neurosurgical Associates of Lancaster in Lancaster, Pa.
“Now more clinicians can utilize MRIs to improve quality of care among a patient population with complex needs,” added Timothy Deer, M.D., the president and chief executive officer with the Spine and Nerve Centers of the Virginias in West Virginia. “It allows clinicians to get to the source of a particular issue in less time and without fear of compromising safety or creating complications.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
